Recent Updates
Recently added Catalysts
MGNX Negative Sentiment Score: 20/100

MacroGenics, Inc. Securities Fraud Class Action Lawsuit Pending: Contact The Gross Law Firm Before September 24, 2024 to Discuss Your Rights – MGNX

Key Takeaway: MacroGenics, Inc. is facing a class action lawsuit due to allegations that the company misrepresented the safety of its drug vobramitamab duocarmazine during its TAMARACK Phase 2 study. Following the release of concerning safety data on May 9, 2024, the company's stock plummeted by 77.4%, leading to significant investor losses. Shareholders who purchased shares between March 7, 2024, and May 9, 2024, are encouraged to contact The Gross Law Firm to discuss their rights and the possibility of serving as lead plaintiff. The deadline for participation in the lawsuit is September 24, 2024.

Market Sentiment Analysis

CONCERNS & RISKS

  • Class action lawsuit due to allegations of fraud regarding safety data.
  • Stock declined 77.4% following revelations about drug dangers.
  • Potential legal consequences for MacroGenics, impacting investor confidence.
  • Shareholders are prompted to register before the deadline to protect their rights.

Full Press Release Details

NEW YORK, Aug. 07, 2024 (GLOBE NEWSWIRE) -- The Gross Law Firm issues the following notice to shareholders of MacroGenics, Inc. (NASDAQ: MGNX).
Shareholders who purchased shares of MGNX during the class period listed are encouraged to contact the firm regarding possible lead plaintiff appointment. Appointment as lead plaintiff is not required to partake in any recovery.
CLASS PERIOD: March 7, 2024 to May 9, 2024
ALLEGATIONS: During the class period, Defendants made material misrepresentations about the safety data from its TAMARACK Phase 2 study of vobramitamab duocarmazine. On May 9, 2024, the investing public learned that the drug was significantly more dangerous than defendants had previously represented. Following this news, MGNX’s stock declined 77.4% due to a drop of $11.36/share.
DEADLINE: September 24, 2024 Shareholders should not delay in registering for this class action. Register your information here: https://securitiesclasslaw.com/securities/macrogenics-inc-loss-submission-form-2/?id=94047&from=3
NEXT STEPS FOR SHAREHOLDERS: Once you register as a shareholder who purchased shares of MGNX during the timeframe listed above, you will be enrolled in a portfolio monitoring software to provide you with status updates throughout the lifecycle of the case. The deadline to seek to be a lead plaintiff is September 24, 2024. There is no cost or obligation to you to participate in this case.
WHY GROSS LAW FIRM? The Gross Law Firm is a nationally recognized class action law firm, and our mission is to protect the rights of all investors who have suffered as a result of deceit, fraud, and illegal business practices. The Gross Law Firm is committed to ensuring that companies adhere to responsible business practices and engage in good corporate citizenship. The firm seeks recovery on behalf of investors who incurred losses when false and/or misleading statements or the omission of material information by a company lead to artificial inflation of the company's stock. Attorney advertising. Prior results do not guarantee similar outcomes.
15 West 38th Street, 12th floor
Phone: (646) 453-8903

Tags

Frequently Asked Questions

What is the class period for MacroGenics shareholders?

The class period for MacroGenics shareholders is from March 7, 2024, to May 9, 2024.

What were the allegations against MacroGenics?

The allegations involve material misrepresentations about the safety of vobramitamab duocarmazine during its Phase 2 study.

How much did MGNX's stock decline?

MGNX's stock declined by 77.4%, losing $11.36 per share after safety concerns arose.

What is the deadline to register for the class action?

The deadline to register for the class action is September 24, 2024.

Is there a cost to participate in the class action?

There is no cost or obligation for shareholders to participate in this case.

Last updated: Aug 7, 2024